ELTPOTCPharmaceutical PreparationsFiscal year ends March 31

ELITE PHARMACEUTICALS INC /NV/

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.25−0.00 (-1.37%)

Close on Oct 19, 2026

Community

Notes and questions about Elite Pharmaceuticals from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Elite Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ELTP.

Revenue growth33.7% · median 17.9%

Gross margin43.5% · median 57.9%

Operating margin24.8% · median -20.8%

Net margin40.2% · median -144.6%

Advertisement
300 × 250